Accure develops a 1726 nm laser system that utilizes proprietary “treat-to-temperature” technology to target overactive sebaceous glands, a primary cause of acne. This treatment offers a non-systemic solution, achieving an average 70% reduction in acne lesions after four sessions, performed in dermatologists' offices.
Funding
$60.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Acne vulgaris, affecting a significant portion of the global population, is often treated with systemic medications that carry potential side effects. Many patients seek non-systemic alternatives for managing mild to severe inflammatory acne.
Solution
Accure offers a laser-based system designed to target the root cause of acne by selectively heating and damaging overactive sebaceous glands. The Accure Acne Laser System utilizes a 1726 nm wavelength and proprietary "treat-to-temperature" technology to ensure precise and safe energy delivery. Treatments are administered in a dermatologist's office, typically involving four sessions spaced one month apart. Clinical studies have demonstrated a significant reduction in acne lesions following the completion of the treatment course.
Target Audience
The primary customers are dermatologists seeking an in-office, non-systemic laser treatment for patients with acne vulgaris.
Features
- 1726 nm laser for selective targeting of sebaceous glands
- Proprietary "treat-to-temperature" technology for precise energy delivery and safety
- Customizable treatment parameters based on individual patient needs
- Non-systemic approach, avoiding the side effects associated with oral medications
- FDA-cleared for the treatment of mild to severe inflammatory acne vulgaris